Check out our most popular compounded medications! Get Started
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded suspension containing atenolol hydrochloride, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing atenolol are listed in tablet form. No finished atenolol product of any kind is listed in suspension form.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Atenolol is a beta-1 selective beta-blocker; compounding pharmacies prepare it as oral liquids and capsules by prescription.
Atenolol is a cardioselective beta-1 adrenergic blocker. By blocking beta-1 receptors in the heart, it lowers heart rate, blood pressure and the force of contraction; it has no membrane-stabilizing or intrinsic sympathomimetic activity and, because of its low lipid solubility, enters the brain poorly. Manufactured Tenormin tablets (Upsher-Smith) and generic atenolol tablets are FDA-approved to treat hypertension, for long-term management of angina pectoris, and for hemodynamically stable patients with definite or suspected acute heart attack to reduce cardiovascular death. DailyMed lists atenolol only as tablets, alone or with chlorthalidone, so a prescriber may order a compounded oral liquid for a child or a patient who cannot swallow tablets, or a strength that is not manufactured. Compounded preparations are not FDA-approved and require a prescription.
The Tenormin label warns against stopping atenolol suddenly if you have coronary artery disease: severe worsening of angina, heart attack and dangerous heart rhythms have followed abrupt withdrawal of beta-blockers, so it should be tapered under supervision. Do not take atenolol with a very slow heart rate, heart block greater than first degree, cardiogenic shock or overt heart failure. People with asthma or other bronchospastic disease generally should not take beta-blockers. Atenolol can hide signs of low blood sugar and of an overactive thyroid, and should not be given with untreated pheochromocytoma. Verapamil, diltiazem, disopyramide, amiodarone, digoxin and reserpine interact, clonidine withdrawal needs special timing, and NSAIDs such as indomethacin can blunt its effect. Atenolol can cause fetal harm, and breastfed infants have had a slow heart rate; LactMed prefers other agents while nursing a newborn. For dizziness, swelling or shortness of breath, talk to your prescriber or pharmacist.
Atenolol is a beta-1 selective antagonist that competitively blocks beta-2 receptors at higher doses (StatPearls). Per the Tenormin label, about 50 percent of an oral dose is absorbed, peak levels occur at 2 to 4 hours, there is little or no hepatic metabolism, 6 to 16 percent is protein bound, and the elimination half-life is 6 to 7 hours; the absorbed drug is cleared renally in close relation to glomerular filtration rate, so renal impairment affects dosing per prescriber. Labeled indications (Tenormin): hypertension, angina pectoris due to coronary atherosclerosis, and acute myocardial infarction in hemodynamically stable patients. StatPearls lists off-label uses including arrhythmias, migraine prophylaxis, alcohol withdrawal and thyrotoxicosis, and describes atenolol as an alternative to propranolol for infantile hemangiomas; none of these is an FDA-approved indication. Dosing is per prescriber, with a gradual taper when stopping. Monitor heart rate, blood pressure, renal function, signs of heart failure, and glucose in patients with diabetes and in fasting children. LactMed notes that low protein binding (about 10 percent) favors excretion into breastmilk and that about 85 percent renal excretion favors accumulation in infants, especially newborns. Atenolol is not a controlled substance.
Shake the bottle well before every dose so the medication is evenly mixed. Measure with the oral syringe or dosing cup provided, using the milliliter markings, and never a kitchen spoon. Take it by mouth as your label directs. Rinse the syringe after use and recap the bottle.
Water-based suspensions are aqueous preparations. Under USP <795>, a preserved suspension usually carries a beyond-use date of up to 35 days at room temperature or refrigerated; an unpreserved one is refrigerated for up to 14 days. Oil-based suspensions are nonaqueous and may carry up to 90 days. Your label states storage and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take orally
